| Literature DB >> 23933508 |
Annemarie van Nieuwenhuijze1, Marije Koenders, Debbie Roeleveld, Matthew A Sleeman, Wim van den Berg, Ian P Wicks.
Abstract
GM-CSF is a well-known haemopoietic growth factor that is used in the clinic to correct neutropaenia, usually as a result of chemotherapy. GM-CSF also has many pro-inflammatory functions and recent data implicates GM-CSF as a key factor in Th17 driven autoimmune inflammatory conditions. In this review we summarize the findings that have led to the development of GM-CSF antagonists for the treatment of autoimmune diseases like rheumatoid arthritis (RA) and discuss some results of recent clinical trials of these agents.Entities:
Keywords: Autoimmune disease; Autoimmunity; Cytokines; GM-CSF; GM-CSF receptor; Inflammatory disease; Rheumatoid arthritis; T cells; Th17 pathway
Mesh：
Substances：
Year: 2013 PMID： 23933508 DOI： 10.1016/j.molimm.2013.05.002
Source DB: PubMed Journal: Mol Immunol ISSN： 0161-5890 Impact factor: 4.407